<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Ketamine poisoning
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Ketamine poisoning
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Ketamine poisoning
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert J Hoffman, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Evan Schwarz, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael Ganetsky, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 16, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          Ketamine
         </a>
         was synthesized in 1962 by Parke-Davis and first used in humans in 1965 [
         <a href="#rid1">
          1,2
         </a>
         ]. The United States military used ketamine as a field anesthetic during the Vietnam War, and it gradually gained popularity as an induction and maintenance agent for procedural sedation and general anesthesia. In addition to its misuse as a recreational drug, ketamine is used clinically for treatment of psychomotor agitation in the prehospital and emergency settings [
         <a href="#rid3">
          3
         </a>
         ], depression and mood disorders [
         <a href="#rid4">
          4
         </a>
         ], chronic migraine headache [
         <a href="#rid5">
          5
         </a>
         ], status epilepticus [
         <a href="#rid6">
          6
         </a>
         ], and pain [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         This topic will review the presentation and treatment of
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         intoxication as well as poisoning with ketamine analogues and novel psychoactive substances, including deschloroketamine, 2-fluoro-deschlorketamine, methoxketamine, methoxetamine, 2-oxo-PCE, tiletamine, and similar agents. A summary table to facilitate emergency management is provided  (
         <a class="graphic graphic_table graphicRef69157" href="/z/d/graphic/69157.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         Discussions of the use of
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         for procedural sedation and induction for rapid sequence intubation (RSI) are found separately. (See
         <a class="medical medical_review" href="/z/d/html/271.html" rel="external">
          "Induction agents for rapid sequence intubation in adults for emergency medicine and critical care", section on 'Ketamine'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/82857.html" rel="external">
          "Pediatric procedural sedation: Pharmacologic agents", section on 'Ketamine'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/139217.html" rel="external">
          "Procedural sedation in adults in the emergency department: Medication selection, dosing, and discharge criteria", section on 'Ketamine sedation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2746675362">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         By the 1970s,
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         had become a widely used recreational drug, with street names such as K, Special K, KitKat, Vitamin K, ket, and Super K. Ketamine abuse is closely associated worldwide with the use of other "club drugs" including "Molly" or "ecstasy" (3,4-methylenedioxymethamphetamine or MDMA), gamma hydroxybutyrate (GHB), and methamphetamine, often in the setting of large dance parties [
         <a href="#rid8">
          8
         </a>
         ]. A large retrospective review of ketamine exposures reported to United States poison centers over a 16-year period noted that 49 percent of exposures were in patients 16 to 25 years of age, 49 percent were polypharmacy exposures, and 51 percent were ketamine-only exposures [
         <a href="#rid9">
          9
         </a>
         ]. In this study, two deaths occurred in patients with ketamine-only exposures. (See
         <a class="medical medical_review" href="/z/d/html/302.html" rel="external">
          "MDMA (ecstasy) intoxication"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/307.html" rel="external">
          "Gamma hydroxybutyrate (GHB) intoxication"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/311.html" rel="external">
          "Methamphetamine: Acute intoxication"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          PATHOPHYSIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          Ketamine
         </a>
         is an arylcycloalkylamine that is structurally related to phencyclidine (PCP). Ketamine is a dissociative anesthetic and hallucinogen. It acts primarily as an antagonist of the N-methyl-D-aspartate (NMDA) receptor but also possesses some opioid receptor activity and sympathomimetic properties. The latter results in enhanced central and peripheral monoaminergic transmission and inhibition of central and peripheral cholinergic transmission [
         <a href="#rid10">
          10
         </a>
         ]. The primary site of ketamine's central nervous system activity appears to be the thalamocortical projection system, where it causes depression of certain cortical and thalamic functions and stimulation of parts of the limbic system [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          KINETICS AND METABOLISM
         </span>
         <span class="headingEndMark">
          —
         </span>
         Two phases of
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         distribution can be distinguished following intravenous (IV) administration. The first phase corresponds to the anesthetic effect of the drug and is characterized by rapid distribution (half-life of 10 to 16 minutes) and a large volume of distribution due to the drug's high lipid solubility. The second phase represents redistribution from the central nervous system to peripheral tissues, with an elimination half-life of two to three hours.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          Ketamine
         </a>
         undergoes significant first-pass metabolism. The drug is metabolized by hepatic enzymes through demethylation, hydroxylation, and glucuronidation, and then excreted in the urine [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          DOSES AND FORMULATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Common therapeutic dosages of
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         are 3 to 8 mg/kg for intramuscular (IM) use and 0.5 to 4.5 mg/kg for intravenous (IV) use depending upon the procedure and the patient's age [
         <a href="#rid2">
          2
         </a>
         ]. The usual induction dose is 1 to 2 mg/kg. Recreational doses typically range from 75 to 125 mg via the IM or subcutaneous route, 60 to 250 mg intranasally, 50 to 100 mg IV, and 200 to 300 mg orally [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          Ketamine
         </a>
         synthesis is a complex, multistep process that precludes easy, small-scale, clandestine drug production. However, illicit production does still occur. Sources of ketamine sold illicitly include diversion of legitimate veterinary and medical supplies as well as illicit manufacture.
        </p>
        <p>
         The number of medications and designer drugs that are analogs of
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         has increased and includes
         <a class="drug drug_general" data-topicid="120589" href="/z/d/drug information/120589.html" rel="external">
          esketamine
         </a>
         (approved by the US Food and Drug Administration [FDA] for treatment of depression) as well as deschloroketamine, 2-fluoro-2-deschlorketamine, methoxetamine, methoxyketamine, 2-oxo-PCE, and tiletamine. There is limited clinical experience with the toxicity of these analogs, but a spectrum of poisoning that includes fatality has been reported [
         <a href="#rid14">
          14-18
         </a>
         ]. The increasing frequency of identification of novel ketamine analogs suggests increasing use and possibly an increase in the frequency of poisonings from these substances in the near future. In the absence of more definitive data, we suggest that clinicians manage poisoning from designer drug analogs of ketamine in a manner similar to that described below for ketamine poisoning. (See
         <a class="local">
          'Management'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          CLINICAL PRESENTATION
         </span>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Vital signs
         </span>
         <span class="headingEndMark">
          —
         </span>
         At low or therapeutic doses (less than 5 mg/kg),
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         may cause slight elevations in heart rate and blood pressure. Higher doses (over 5 mg/kg) have inconsistent cardiovascular effects and may result in hypertension, hypotension, tachycardia, or bradycardia [
         <a href="#rid19">
          19
         </a>
         ]. Massive overdose or use with other sedatives may result in respiratory depression or apnea [
         <a href="#rid20">
          20
         </a>
         ]. One case of malignant hyperthermia has been reported [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Central nervous system effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          Ketamine
         </a>
         is capable of causing a spectrum of central nervous system effects, ranging from mild agitation to coma, depending on the dose and patient susceptibility. Agitation and other psychiatric disturbances caused by ketamine are much less common and less severe than those caused by phencyclidine (PCP).
        </p>
        <p>
         The desired clinical effect of iatrogenic
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         administration varies depending upon the clinical goal. Historically, ketamine has been used most often for sedation or anesthesia. This results from dissociation, or interruption of the patient's sensory perception. The inability to sense pain makes ketamine an effective anesthetic. Reflexes, including those involved in airway protection, are maintained.
        </p>
        <p>
         Lower doses, sometimes referred to as subdissociative doses, have been used to treat pain and acute depression [
         <a href="#rid22">
          22
         </a>
         ]. Subdissociative doses of
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         result in altered perception but allow patients to maintain full or nearly full alertness.
        </p>
        <p>
         In overdose,
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         , like PCP, is capable of inducing coma and deep anesthesia. In smaller doses (ie, those preferred by most abusers), ketamine slightly alters sensory perception and acts as a hallucinogen. Effects include slight depression of mental status, diminished alertness, ataxia, and nystagmus. In abuse and with emergence reactions, patients may also experience extreme agitation, fear, and psychiatric disturbance [
         <a href="#rid23">
          23-25
         </a>
         ]. The typical presentation of recreational ketamine users who present for medical evaluation is impaired consciousness [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
         Emergence reactions occur as the effects of therapeutic doses of
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         dissipate following sedation. The phenomenon may involve vivid dreams, "out-of-body" experiences, and illusions. Reactions can be associated with excitement, confusion, euphoria, or fear. The incidence of emergence reactions may be lower than previously thought [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
         The following manifestations may also be seen with
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         intoxication:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Amnesia (not as prominent as with benzodiazepines)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ataxia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Moderate dilatation of pupils
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased muscle tone
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Absence-like effect (patient appears awake but is unresponsive)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Respiratory and airway effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          Ketamine
         </a>
         is a preferred anesthetic because, in therapeutic doses, it does not cause cardiopulmonary depression [
         <a href="#rid27">
          27
         </a>
         ]. In massive doses or in combination with other sedative agents, however, respiratory depression and apnea can occur [
         <a href="#rid28">
          28-30
         </a>
         ]. Independent idiosyncratic effects seen after iatrogenic administration include laryngospasm, hypersalivation, and bronchorrhea [
         <a href="#rid20">
          20,31-33
         </a>
         ]. The cause of these phenomena is unclear.
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Cardiovascular effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         In therapeutic doses,
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         can exert a mild sympathomimetic effect on the cardiovascular system with slight increases in blood pressure and heart rate [
         <a href="#rid34">
          34
         </a>
         ]. Hypotension and bradycardia have been reported but are rare. Ketamine increases myocardial oxygen demand and may increase the risk of acute coronary syndrome, particularly in patients with additional risk factors for cardiovascular disease.
        </p>
        <p class="headingAnchor" id="H51338108">
         <span class="h2">
          Ocular effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         While less common with
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         than phencyclidine (PCP) intoxication, nystagmus may be seen and may be rotatory, vertical, or horizontal [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Other effects from subacute and chronic exposure
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         abuse may lead to neuropsychiatric impairment, urologic injury, referred to as ketamine-induced ulcerative cystitis or ketamine-induced uropathy, or hepatic injury. The mechanism of ketamine-associated uropathy and hepatic injury remains unclear.
        </p>
        <p class="headingAnchor" id="H389850880">
         <span class="h3">
          Urologic injury
         </span>
         <span class="headingEndMark">
          —
         </span>
         First reported in 2007, ketamine-induced urologic injury is presumed to result from irritation of the urologic system and may include urge incontinence, decreased bladder compliance, decreased bladder volume, detrusor overactivity, hematuria, and rarely hydronephrosis or papillary necrosis [
         <a href="#rid35">
          35-37
         </a>
         ]. Ketamine-induced uropathy is being diagnosed and reported with increasing frequency, though it is unclear if this is due to an increase in incidence or clinician awareness. Ketamine-induced uropathy appears to be a permanent injury, though patients may have symptomatic improvement through medical or surgical treatment. In 2016 and 2018, studies of
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         abusers in Malaysia and China using data compiled from questionnaires reported a high prevalence of erectile dysfunction, with long-term users more likely to experience the problem [
         <a href="#rid38">
          38,39
         </a>
         ]. Renal injury, including hydronephrosis as well as renal failure and end-stage renal disease, has also been noted in chronic ketamine abusers [
         <a href="#rid40">
          40,41
         </a>
         ]. Notably, worse outcomes were noted in patients with concomitant markers of hepatic injury including elevated gamma-glutamyl transpeptidase, AST, and ALT.
        </p>
        <p class="headingAnchor" id="H2088265445">
         <span class="h3">
          Hepatobiliary injury
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sclerosing cholangitis and hepatic injuries have been reported in patients who received a
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         infusion to maintain sedation during mechanical ventilation. In the wake of the coronavirus disease 2019 (COVID-19) pandemic, numerous case reports and series have documented sclerosing cholangitis, jaundice, decompensated cirrhosis, and hepatic failure (sometimes fatal) in patients who received prolonged ketamine infusions [
         <a href="#rid42">
          42
         </a>
         ]. Cholangiopathy and sclerosing cholangitis in association with ketamine infusion was previously noted in a large French case series of 293 patients who received ketamine infusion during management in a burn center [
         <a href="#rid43">
          43
         </a>
         ]. The risk of sclerosing cholangitis and hepatic injury appears to be dose related, as lesser doses appear to result in this complication less frequently. Chronic abuse of ketamine has previously been described as a risk factor for sclerosing cholangitis. .
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Adverse effects following therapeutic adminstration
         </span>
         <span class="headingEndMark">
          —
         </span>
         When administered correctly,
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         is generally safe. Nevertheless, respiratory depression, apnea, hypotension, bradycardia, myocardial infarction, and death have all been reported after ketamine overdose or overly rapid infusion.
        </p>
        <p>
         The most common adverse events after iatrogenic administration include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vomiting
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Psychiatric disturbance/emergence phenomenon
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Respiratory depression
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Laryngospasm
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Salivation
        </p>
        <p>
        </p>
        <p>
         These effects occur after intravenous (IV) use. Since most recreational users insufflate (ie, "snort")
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         , the complications listed are rarely observed outside of the hospital.
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Adverse effects after illicit use
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          Ketamine
         </a>
         abusers are typically adolescents or young adults. However, according to one case series, the age of abusers ranges from 13 to 60 years [
         <a href="#rid19">
          19
         </a>
         ]. Overwhelmingly, impaired consciousness is the presenting complaint. Patients may have white powder in or on their nose at time of presentation. Symptoms from ketamine abuse appear to resolve quickly in most instances. In another small case series, half of patients who abused ketamine were asymptomatic by the time a clinician evaluated them in the emergency department, while half complained of anxiety, chest pain, or palpitations [
         <a href="#rid34">
          34
         </a>
         ]. Hallucinations usually resolved prior to evaluation. Tachycardia was the most common physical finding; hypertension was also noted.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          Ketamine
         </a>
         is frequently abused in combination with other illicit drugs, such as amphetamines, MDMA, and cocaine [
         <a href="#rid44">
          44,45
         </a>
         ]. Toxicity from these other agents is common. In New York City between 1997 and 2000, 12 deaths occurred in people abusing ketamine, but in all cases, multiple drugs were involved. Death following IV injection of ketamine alone has been reported, but such events are likely rare [
         <a href="#rid9">
          9,27
         </a>
         ]. Animal data suggest that combined use of caffeine and ketamine exacerbates toxicity [
         <a href="#rid46">
          46
         </a>
         ]. This may be important in some cases, as use of caffeinated energy drinks is common in the settings where ketamine is often used recreationally.
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis for
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         toxicity varies with the major presenting symptoms. (See
         <a class="medical medical_review" href="/z/d/html/324.html" rel="external">
          "General approach to drug poisoning in adults"
         </a>
         .)
        </p>
        <p>
         Coma can be caused by many toxins, including opioids, alcohols, and sedative hypnotic agents. The clinician must also consider neurologic injury, hypoglycemia, and hypoxia in any comatose patient  (
         <a class="graphic graphic_table graphicRef59515" href="/z/d/graphic/59515.html" rel="external">
          table 2
         </a>
         and
         <a class="graphic graphic_table graphicRef65571" href="/z/d/graphic/65571.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/5104.html" rel="external">
          "Stupor and coma in adults"
         </a>
         .)
        </p>
        <p>
         The differential diagnosis for psychomotor agitation or hallucinosis includes intoxication with drugs such as phencyclidine (PCP), lysergic acid diethylamide (LSD), cocaine, amphetamines, and a variety of novel psychoactive substances. Withdrawal from ethanol or sedative hypnotic agents may also cause such symptoms. Psychiatric and other medical causes are far more common etiologies of psychomotor agitation than is
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         toxicity. (See
         <a class="medical medical_review" href="/z/d/html/323.html" rel="external">
          "Management of moderate and severe alcohol withdrawal syndromes"
         </a>
         .)
        </p>
        <p>
         Focal neurologic findings, such as nystagmus and ataxia, can be caused by intoxication with such drugs as PCP,
         <a class="drug drug_general" data-topicid="8893" href="/z/d/drug information/8893.html" rel="external">
          dextromethorphan
         </a>
         , and anticonvulsants such as
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         and
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         , and by injury to the central nervous system. (See
         <a class="medical medical_review" href="/z/d/html/5109.html" rel="external">
          "Overview of nystagmus"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diagnosis of
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         intoxication is based on history and clinical evidence; no definitive laboratory test is routinely available. Although ketamine and phencyclidine are structurally similar, there is no reliable cross-reactivity between ketamine metabolites and available phencyclidine (PCP) detection assays.
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          LABORATORY EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Routine laboratory evaluation of the poisoned patient should include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fingerstick glucose to detect hypoglycemia as the cause of any alteration in mental status
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          Acetaminophen
         </a>
         and salicylate levels to rule out these common coingestions
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Electrocardiogram (ECG) to rule out conduction system poisoning by drugs that effect the QRS or QTc intervals
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pregnancy test in women of childbearing age
        </p>
        <p>
        </p>
        <p>
         Clinicians should obtain additional tests based on clinical findings. In patients experiencing chest pain, cardiac enzymes may be indicated. Muscle rigidity and severe agitation from
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         overdose can cause rhabdomyolysis. If this is a concern, serum creatine kinase and urine myoglobin should be obtained.
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management of problems commonly encountered with
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         intoxication is described below. A summary table to facilitate emergency management is provided  (
         <a class="graphic graphic_table graphicRef69157" href="/z/d/graphic/69157.html" rel="external">
          table 1
         </a>
         ). A general approach to the poisoned patient is found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/324.html" rel="external">
          "General approach to drug poisoning in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h2">
          Airway and breathing support
         </span>
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h3">
          Laryngospasm
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ketamine-induced laryngospasm is rare and most frequently occurs in infants [
         <a href="#rid31">
          31
         </a>
         ]. It is typically self-limited, usually lasting less than one minute. Respiratory support should include administration of supplemental oxygen and positive-pressure ventilation by bag-valve mask. In circumstances when laryngospasm does not resolve with basic airway support, endotracheal intubation may be needed.
        </p>
        <p>
         The management of laryngospasm in children, including laryngospasm notch pressure, is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/117125.html" rel="external">
          "Complications of pediatric airway management for anesthesia", section on 'Management of laryngospasm'
         </a>
         .)
        </p>
        <p>
         Pediatric airway management is otherwise reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6383.html" rel="external">
          "Basic airway management in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6316.html" rel="external">
          "Technique of emergency endotracheal intubation in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15860.html" rel="external">
          "Supraglottic airway devices in children with difficult airways"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h3">
          Respiratory depression
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypoxia during administration of
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         for procedural sedation most frequently occurs from positional airway compromise; respiratory depression or apnea is much less common. Clinicians should provide supplemental oxygen and ensure airway patency with basic maneuvers such as head-tilt chin-lift or jaw-thrust. For apnea or respiratory insufficiency, clinicians should provide assisted ventilation using a bag-valve mask. Rarely, endotracheal intubation may be needed, if apnea persists. (See
         <a class="medical medical_review" href="/z/d/html/267.html" rel="external">
          "Basic airway management in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6316.html" rel="external">
          "Technique of emergency endotracheal intubation in children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h3">
          Excessive salivation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Extreme sialorrhea is a known complication of
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         administration. Suction and proper positioning should be performed to prevent aspiration. Pharmacologic treatment is needed if respiratory compromise develops, continual suctioning is necessary, or excessive saliva interferes with a necessary procedure (eg, laceration repair). Such treatment involves use of an anticholinergic agent, usually
         <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">
          glycopyrrolate
         </a>
         (5 mcg/kg IV, may be repeated once every two to three minutes; maximum single dose is 0.2 mg; maximum total dose is 0.8 mg) or
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         (0.01 to 0.02 mg/kg IV; minimum dose 0.1 mg; maximum dose 1.2 mg). Glycopyrrolate may be more effective at reducing secretions than atropine, although this has not been well studied, and it is less likely to produce cardiac and central nervous system effects.
        </p>
        <p>
         When providing procedural sedation, some clinicians coadminister
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         with
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         to prevent salivation, but there is little evidence to support this practice. Coadministration is not a necessity, but atropine or
         <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">
          glycopyrrolate
         </a>
         should be readily available when ketamine is administered [
         <a href="#rid47">
          47,48
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6330.html" rel="external">
          "Procedural sedation in children: Approach"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h2">
          Cardiovascular support
         </span>
         <span class="headingEndMark">
          —
         </span>
         Significant cardiovascular complications are uncommon and may be managed using standard treatments. After securing the airway and breathing if necessary, clinicians should treat bradycardia with
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         (0.01 to 0.02 mg/kg intravenously [IV]; minimum dose 0.1 mg IV; may be repeated every five minutes to a maximum total dose of 3 mg). Tachycardia from psychomotor agitation is treated with benzodiazepines. (See
         <a class="medical medical_review" href="/z/d/html/278.html" rel="external">
          "Advanced cardiac life support (ACLS) in adults", section on 'Bradycardia'
         </a>
         and
         <a class="local">
          'Psychomotor agitation, muscle rigidity, hallucination'
         </a>
         below.)
        </p>
        <p>
         Treatment of hypotension begins with IV boluses of crystalloid. Hypotension requiring treatment with vasopressors is uncommon, but sympathomimetic agents such as
         <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">
          norepinephrine
         </a>
         and
         <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">
          dopamine
         </a>
         may be used.
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h2">
          Supportive care
         </span>
         <span class="headingEndMark">
          —
         </span>
         Once airway, breathing, and circulation are secured as necessary, supportive care is typically the only treatment needed for
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         toxicity. The adverse effects of ketamine typically last between 15 minutes and several hours; prolonged care is rarely needed.
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h2">
          Psychomotor agitation, muscle rigidity, hallucination
         </span>
         <span class="headingEndMark">
          —
         </span>
         Psychiatric disturbance from
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         toxicity is generally short lived. Minimizing stimuli, such as light and noise, is helpful. When restraint is needed, physical restraints should only be used until adequate chemical sedation is provided. Benzodiazepines are the mainstay of such treatment. They are helpful in managing fear, panic, hallucinations, and emergence reactions.
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          Lorazepam
         </a>
         may be used in 1 to 2 mg IV doses until the desired level of sedation is achieved. Alternatively,
         <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">
          diazepam
         </a>
         in 5 to 10 mg IV doses may be used.
        </p>
        <p>
         Muscle rigidity can occur with IV
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         use but is generally without consequence.
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          Lorazepam
         </a>
         may be given in the doses above for muscle relaxation if needed.
        </p>
        <p>
         Butyrophenones (such as
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         and
         <a class="drug drug_general" data-topicid="9395" href="/z/d/drug information/9395.html" rel="external">
          droperidol
         </a>
         ) and other antipsychotic agents should not be used to treat agitation [
         <a href="#rid49">
          49
         </a>
         ]. They interfere with heat dissipation, may prolong the QTc interval, and may reduce the seizure threshold.
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h2">
          Gastrointestinal decontamination
         </span>
         <span class="headingEndMark">
          —
         </span>
         Gastrointestinal (GI) decontamination is almost never indicated. When used illicitly,
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         is usually snorted, and occasionally injected IV or intramuscularly (IM). Toxicity from these routes of administration would not be affected by GI decontamination.
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h2">
          Enhanced elimination
         </span>
         <span class="headingEndMark">
          —
         </span>
         No enhanced elimination technique is available for
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         overdose. A risky and outmoded method of enhanced elimination of phencyclidine (PCP), urine acidification, has never been tested in ketamine and should
         <strong>
          not
         </strong>
         be used.
        </p>
        <p class="headingAnchor" id="H27">
         <span class="h1">
          PEDIATRIC CONSIDERATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ketamine-induced laryngospasm occurs more commonly in infants or young children than adults. Management is discussed above (see
         <a class="local">
          'Laryngospasm'
         </a>
         above). Child protective services should be consulted for children too young to have abused
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         intentionally.
        </p>
        <p class="headingAnchor" id="H28">
         <span class="h1">
          DISPOSITION
         </span>
         <span class="headingEndMark">
          —
         </span>
         In extraordinarily rare instances of end-organ toxicity, such as myocardial infarction, patients require admission to an intensive care unit. In most cases, patients may be discharged after symptoms have resolved, usually within six hours. No specific follow-up is needed for most of the adverse events previously mentioned. Drug abusers should be referred for drug counseling and rehabilitation.
        </p>
        <p class="headingAnchor" id="H90350064">
         <span class="h1">
          ADDITIONAL RESOURCES
         </span>
        </p>
        <p class="headingAnchor" id="H1739896942">
         <span class="h2">
          Regional poison control centers
         </span>
         <span class="headingEndMark">
          —
         </span>
         Regional poison control centers in the United States are available at all times for consultation on patients with known or suspected poisoning, and who may be critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have medical toxicologists available for bedside consultation. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. Contact information for poison centers around the world is provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/138307.html" rel="external">
          "Society guideline links: Regional poison control centers"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14436004">
         <span class="h2">
          Society guideline links
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112689.html" rel="external">
          "Society guideline links: General measures for acute poisoning treatment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H29">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Emergency management of severe complications
         </strong>
         – A summary table to facilitate emergency management of severe complications from
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         poisoning is provided  (
         <a class="graphic graphic_table graphicRef69157" href="/z/d/graphic/69157.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical presentation after recreational use
         </strong>
         –
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          Ketamine
         </a>
         is a dissociative anesthetic and hallucinogen. Patients who use ketamine illicitly usually insufflate ("snort") or ingest the drug. They often have no medical complaints. Some describe anxiety, chest pain, palpitations, or hallucinations. Tachycardia is a common physical finding. Massive overdose or use with other sedatives may result in respiratory depression or apnea. Ketamine is capable of causing a spectrum of central nervous system effects, ranging from mild agitation to coma, depending upon the dose and patient susceptibility. It is frequently abused in combination with other illicit drugs, such as amphetamine, MDMA, and cocaine. (See
         <a class="local">
          'Clinical presentation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Possible iatrogenic effects from medical use
         </strong>
         – When administered correctly for medical treatment,
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         is generally safe. Nevertheless, patients given ketamine intravenously (IV) can develop problems, including:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Psychiatric disturbance/emergence phenomenon
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Respiratory depression
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Laryngospasm
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Salivation
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Respiratory depression, apnea, hypotension, bradycardia, myocardial infarction, and death are rare but have been reported after iatrogenic overdose or overly rapid infusion of
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         . (See
         <a class="local">
          'Clinical presentation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis and diagnostic testing
         </strong>
         – Diagnosis of
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         intoxication is based on history and clinical evidence; no definitive laboratory test is readily available. Tests obtained as part of the evaluation of a patient with suspected ketamine poisoning are determined based on clinical circumstances described. (See
         <a class="local">
          'Diagnosis'
         </a>
         above and
         <a class="local">
          'Laboratory evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Laryngospasm and respiratory depression
         </strong>
         – Ketamine-induced laryngospasm is rare but most frequently occurs in infants. It is typically self-limited, lasting less than one minute. Assisted ventilation using a bag-valve mask should be provided. Should laryngospasm not resolve with basic airway support, endotracheal intubation may be needed. Hypoxia during procedural sedation with
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         is caused most often by positional airway compromise, but true respiratory depression or apnea may occur, requiring airway intervention. A summary table to facilitate emergency management of ketamine poisoning is provided  (
         <a class="graphic graphic_table graphicRef69157" href="/z/d/graphic/69157.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Airway and breathing support'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Excessive salivation
         </strong>
         –
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          Ketamine
         </a>
         can cause extreme salivation (sialorrhea). Suction and positioning should be performed to prevent aspiration. We suggest pharmacologic treatment for sialorrhea if respiratory compromise develops, continual suctioning is necessary, or excessive saliva interferes with a necessary procedure (eg, laceration repair) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Either
         <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">
          glycopyrrolate
         </a>
         (5 mcg/kg IV, may be repeated once every two to three minutes; maximum single dose is 0.2 mg; maximum total dose is 0.8 mg) or
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         (0.01 to 0.02 mg/kg IV; minimum dose 0.1 mg; maximum dose 1.2 mg) can be administered. (See
         <a class="local">
          'Excessive salivation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cardiovascular complications not common
         </strong>
         – Significant cardiovascular complications are uncommon and are managed using standard treatments. (See
         <a class="local">
          'Cardiovascular support'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Agitation
         </strong>
         – Psychomotor agitation can occur with overdose. When necessary, we suggest treatment with benzodiazepines (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). In adults,
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         may be used in 1 to 2 mg IV doses until the desired level of sedation is achieved. Butyrophenones (such as
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         and
         <a class="drug drug_general" data-topicid="9395" href="/z/d/drug information/9395.html" rel="external">
          droperidol
         </a>
         ) interfere with heat dissipation, may prolong the QTc, and may reduce the seizure threshold. We suggest that butyrophenones
         <strong>
          not
         </strong>
         be used to sedate patients with
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         toxicity (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Psychomotor agitation, muscle rigidity, hallucination'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Disposition
         </strong>
         – In most cases,
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         intoxication produces no significant adverse effects, and patients may be discharged after a period of asymptomatic observation, usually within six hours. (See
         <a class="local">
          'Disposition'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Corssen G, Domino EF. Dissociative anesthesia: further pharmacologic studies and first clinical experience with the phencyclidine derivative CI-581. Anesth Analg 1966; 45:29.
          </a>
         </li>
         <li class="breakAll">
          Miller RD. Miller's Anesthesia, 6th, Elsevier Churchill Livingstone, New York 2005.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Isbister GK, Calver LA, Downes MA, Page CB. Ketamine as Rescue Treatment for Difficult-to-Sedate Severe Acute Behavioral Disturbance in the Emergency Department. Ann Emerg Med 2016; 67:581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanacora G, Frye MA, McDonald W, et al. A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. JAMA Psychiatry 2017; 74:399.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lauritsen C, Mazuera S, Lipton RB, Ashina S. Intravenous ketamine for subacute treatment of refractory chronic migraine: a case series. J Headache Pain 2016; 17:106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fang Y, Wang X. Ketamine for the treatment of refractory status epilepticus. Seizure 2015; 30:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goel AP, Maher DP, Cohen SP. Ketamine: miracle drug or latest fad? Pain Manag 2017; 7:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fox J, Smith A, Yale A, et al. Drugs of Abuse and Novel Psychoactive Substances at Outdoor Music Festivals in Colorado. Subst Use Misuse 2018; 53:1203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ni A, Lee Cantrell F, Clark RF. Ketamine exposure demographics and outcomes over 16 years as reported to US poison centers. Am J Emerg Med 2018; 36:1459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adams HA. [Mechanisms of action of ketamine]. Anaesthesiol Reanim 1998; 23:60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miyasaka M, Domino EF. Neural mechanisms of ketamine-induced anesthesia. Int J Neuropharmacol 1968; 7:557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kohrs R, Durieux ME. Ketamine: teaching an old drug new tricks. Anesth Analg 1998; 87:1186.
          </a>
         </li>
         <li class="breakAll">
          Report on the risk assessment of ketamine in the framework of the joint action on new synthetic drugs. European Monitoring Centre for Drugs and Drug Addiction. 2002.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ward J, Rhyee S, Plansky J, Boyer E. Methoxetamine: a novel ketamine analog and growing health-care concern. Clin Toxicol (Phila) 2011; 49:874.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shields JE, Dargan PI, Wood DM, et al. Methoxetamine associated reversible cerebellar toxicity: three cases with analytical confirmation. Clin Toxicol (Phila) 2012; 50:438.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hill SL, Harbon SC, Coulson J, et al. Methoxetamine toxicity reported to the National Poisons Information Service: clinical characteristics and patterns of enquiries (including the period of the introduction of the UK's first Temporary Class Drug Order). Emerg Med J 2014; 31:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corazza O, Assi S, Schifano F. From "Special K" to "Special M": the evolution of the recreational use of ketamine and methoxetamine. CNS Neurosci Ther 2013; 19:454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wikström M, Thelander G, Dahlgren M, Kronstrand R. An accidental fatal intoxication with methoxetamine. J Anal Toxicol 2013; 37:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ng SH, Tse ML, Ng HW, Lau FL. Emergency department presentation of ketamine abusers in Hong Kong: a review of 233 cases. Hong Kong Med J 2010; 16:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reich DL, Silvay G. Ketamine: an update on the first twenty-five years of clinical experience. Can J Anaesth 1989; 36:186.
          </a>
         </li>
         <li class="breakAll">
          Martindale: The Complete Drug Reference, 34th ed, Sweetman S (Ed), Pharmaceutical Press, London 2005.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Motov S, Drapkin J, Likourezos A, et al. Sub-dissociative dose ketamine administration for managing pain in the emergency department. World J Emerg Med 2018; 9:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green SM, Li J. Ketamine in adults: what emergency physicians need to know about patient selection and emergence reactions. Acad Emerg Med 2000; 7:278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garfield JM, Garfield FB, Stone JG, et al. A comparison of psychologic responses to ketamine and thiopental--nitrous oxide--halothane anesthesia. Anesthesiology 1972; 36:329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lahti AC, Weiler MA, Tamara Michaelidis BA, et al. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 2001; 25:455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green SM, Sherwin TS. Incidence and severity of recovery agitation after ketamine sedation in young adults. Am J Emerg Med 2005; 23:142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lalonde BR, Wallage HR. Postmortem blood ketamine distribution in two fatalities. J Anal Toxicol 2004; 28:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green SM, Clark R, Hostetler MA, et al. Inadvertent ketamine overdose in children: clinical manifestations and outcome. Ann Emerg Med 1999; 34:492.
          </a>
         </li>
         <li class="breakAll">
          Dillon JB. Clinical experience with repeated ketamine administration for procedures requiring anesthesia. In: Ketamine, Kreuscher H (Ed), Spring-Verlag, Berlin 1969.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith JA, Santer LJ. Respiratory arrest following intramuscular ketamine injection in a 4-year-old child. Ann Emerg Med 1993; 22:613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green SM, Rothrock SG, Lynch EL, et al. Intramuscular ketamine for pediatric sedation in the emergency department: safety profile in 1,022 cases. Ann Emerg Med 1998; 31:688.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murphy JL Jr. Hypertension and pulmonary oedema associated with ketamine administration in a patient with a history of substance abuse. Can J Anaesth 1993; 40:160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pandey CK, Mathur N, Singh N, Chandola HC. Fulminant pulmonary edema after intramuscular ketamine. Can J Anaesth 2000; 47:894.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiner AL, Vieira L, McKay CA, Bayer MJ. Ketamine abusers presenting to the emergency department: a case series. J Emerg Med 2000; 18:447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shahani R, Streutker C, Dickson B, Stewart RJ. Ketamine-associated ulcerative cystitis: a new clinical entity. Urology 2007; 69:810.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Middela S, Pearce I. Ketamine-induced vesicopathy: a literature review. Int J Clin Pract 2011; 65:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gray T, Dass M. Ketamine cystitis: an emerging diagnostic and therapeutic challenge. Br J Hosp Med (Lond) 2012; 73:576.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suppiah B, Vicknasingam B, Singh D, Narayanan S. Erectile Dysfunction among People Who Use Ketamine and Poly-Drugs. J Psychoactive Drugs 2016; 48:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang SS, Jang MY, Lee KH, et al. Sexual and bladder dysfunction in male ketamine abusers: A large-scale questionnaire study. PLoS One 2018; 13:e0207927.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ou SH, Wu LY, Chen HY, et al. Risk of Renal Function Decline in Patients with Ketamine-Associated Uropathy. Int J Environ Res Public Health 2020; 17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manongi N, Yoon SH, Luo JJ, Trivedi P. Severe Ketamine-Induced Uropathy Associated With Cholangiopathy Requiring Percutaneous Nephrostomy. Cureus 2022; 14:e30443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keta-Cov research group. Electronic address:
           <span class="__cf_email__" data-cfemail="92e4fbfcf1f7fce6bcfff3fefef7e6d2f3e2fae2bcf4e0">
            [email protected]
           </span>
           , Keta-Cov research group. Intravenous ketamine and progressive cholangiopathy in COVID-19 patients. J Hepatol 2021; 74:1243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Tymowski C, Dépret F, Dudoignon E, et al. Ketamine-induced cholangiopathy in ARDS patients. Intensive Care Med 2021; 47:1173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wood DM, Nicolaou M, Dargan PI. Epidemiology of recreational drug toxicity in a nightclub environment. Subst Use Misuse 2009; 44:1495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gill JR, Stajíc M. Ketamine in non-hospital and hospital deaths in New York City. J Forensic Sci 2000; 45:655.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hsu HR, Mei YY, Wu CY, et al. Behavioural and toxic interaction profile of ketamine in combination with caffeine. Basic Clin Pharmacol Toxicol 2009; 104:379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pruitt JW, Goldwasser MS, Sabol SR, Prstojevich SJ. Intramuscular ketamine, midazolam, and glycopyrrolate for pediatric sedation in the emergency department. J Oral Maxillofac Surg 1995; 53:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toft P, Rømer UD. Glycopyrrolate compared with atropine in association with ketamine anaesthesia. Acta Anaesthesiol Scand 1987; 31:438.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chudnofsky CR, Weber JE, Stoyanoff PJ, et al. A combination of midazolam and ketamine for procedural sedation and analgesia in adult emergency department patients. Acad Emerg Med 2000; 7:228.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 298 Version 22.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5325977" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Dissociative anesthesia: further pharmacologic studies and first clinical experience with the phencyclidine derivative CI-581.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5325977" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Dissociative anesthesia: further pharmacologic studies and first clinical experience with the phencyclidine derivative CI-581.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26899459" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Ketamine as Rescue Treatment for Difficult-to-Sedate Severe Acute Behavioral Disturbance in the Emergency Department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28249076" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27878523" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Intravenous ketamine for subacute treatment of refractory chronic migraine: a case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26216679" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Ketamine for the treatment of refractory status epilepticus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28762282" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Ketamine: miracle drug or latest fad?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29148866" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Drugs of Abuse and Novel Psychoactive Substances at Outdoor Music Festivals in Colorado.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29754964" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Ketamine exposure demographics and outcomes over 16 years as reported to US poison centers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9707750" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : [Mechanisms of action of ketamine].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5753175" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Neural mechanisms of ketamine-induced anesthesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9806706" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Ketamine: teaching an old drug new tricks.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9806706" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Ketamine: teaching an old drug new tricks.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21981756" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Methoxetamine: a novel ketamine analog and growing health-care concern.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22578175" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Methoxetamine associated reversible cerebellar toxicity: three cases with analytical confirmation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23349353" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Methoxetamine toxicity reported to the National Poisons Information Service: clinical characteristics and patterns of enquiries (including the period of the introduction of the UK's first Temporary Class Drug Order).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23421859" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : From "Special K" to "Special M": the evolution of the recreational use of ketamine and methoxetamine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23111916" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : An accidental fatal intoxication with methoxetamine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20124567" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Emergency department presentation of ketamine abusers in Hong Kong: a review of 233 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2650898" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Ketamine: an update on the first twenty-five years of clinical experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2650898" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Ketamine: an update on the first twenty-five years of clinical experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30181791" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Sub-dissociative dose ketamine administration for managing pain in the emergency department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10730837" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Ketamine in adults: what emergency physicians need to know about patient selection and emergence reactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5020642" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : A comparison of psychologic responses to ketamine and thiopental--nitrous oxide--halothane anesthesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11557159" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Effects of ketamine in normal and schizophrenic volunteers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15765332" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Incidence and severity of recovery agitation after ketamine sedation in young adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14987429" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Postmortem blood ketamine distribution in two fatalities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10499950" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Inadvertent ketamine overdose in children: clinical manifestations and outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10499950" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Inadvertent ketamine overdose in children: clinical manifestations and outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8442556" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Respiratory arrest following intramuscular ketamine injection in a 4-year-old child.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9624307" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Intramuscular ketamine for pediatric sedation in the emergency department: safety profile in 1,022 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8443855" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Hypertension and pulmonary oedema associated with ketamine administration in a patient with a history of substance abuse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10989861" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Fulminant pulmonary edema after intramuscular ketamine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10802423" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Ketamine abusers presenting to the emergency department: a case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17482909" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Ketamine-associated ulcerative cystitis: a new clinical entity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21155941" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Ketamine-induced vesicopathy: a literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23124288" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Ketamine cystitis: an emerging diagnostic and therapeutic challenge.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27014841" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Erectile Dysfunction among People Who Use Ketamine and Poly-Drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30485367" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Sexual and bladder dysfunction in male ketamine abusers: A large-scale questionnaire study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33020445" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Risk of Renal Function Decline in Patients with Ketamine-Associated Uropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36276597" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Severe Ketamine-Induced Uropathy Associated With Cholangiopathy Requiring Percutaneous Nephrostomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33617925" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Intravenous ketamine and progressive cholangiopathy in COVID-19 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34313797" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Ketamine-induced cholangiopathy in ARDS patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19938928" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Epidemiology of recreational drug toxicity in a nightclub environment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10855972" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Ketamine in non-hospital and hospital deaths in New York City.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19413657" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Behavioural and toxic interaction profile of ketamine in combination with caffeine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7799115" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Intramuscular ketamine, midazolam, and glycopyrrolate for pediatric sedation in the emergency department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3630587" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Glycopyrrolate compared with atropine in association with ketamine anaesthesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10730829" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : A combination of midazolam and ketamine for procedural sedation and analgesia in adult emergency department patients.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
